Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Centessa Pharmaceuticals
Biotech
The GLP-like race to keep us awake and make billions doing it
Experts told Fierce that orexin mimics have much broader potential than narcolepsy and could even become the “GLPs of neuroscience.”
Darren Incorvaia
Aug 31, 2026 11:24am
Lilly pays $6.3B upfront for sleep disorder-focused Centessa
Mar 31, 2026 8:53am
Metabolic marketing master maneuvers to CEO—Chutes & Ladders
Dec 12, 2025 8:30am
Centessa drops hemophilia B drug following Pfizer’s Hympavzi win
Nov 12, 2024 9:45am
Anaptys picks up rival to Biogen autoimmune asset from Centessa
Nov 28, 2023 6:30am
Elevated liver enzymes force Centessa to drop another asset
Aug 10, 2022 9:34am
